Drug
Ft839
Ft839: highest development phase Phase 1/2, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT839 NCT07800871 | Phase 1/2 | ANCA-Associated Vasculitis (AAV) |
Latest
No recent events.
Follow Ft839 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.